Kymera Therapeutics (KYMR) Accumulated Depreciation & Amortization (2019 - 2025)
Historic Accumulated Depreciation & Amortization for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $22.4 million.
- Kymera Therapeutics' Accumulated Depreciation & Amortization rose 5870.37% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year increase of 5870.37%. This contributed to the annual value of $16.1 million for FY2024, which is 5395.59% up from last year.
- Latest data reveals that Kymera Therapeutics reported Accumulated Depreciation & Amortization of $22.4 million as of Q3 2025, which was up 5870.37% from $20.2 million recorded in Q2 2025.
- Kymera Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $22.4 million during Q3 2025, with a 5-year trough of $2.6 million in Q1 2021.
- Over the past 5 years, Kymera Therapeutics' median Accumulated Depreciation & Amortization value was $8.7 million (recorded in 2023), while the average stood at $9.8 million.
- In the last 5 years, Kymera Therapeutics' Accumulated Depreciation & Amortization skyrocketed by 9533.9% in 2021 and then surged by 3523.3% in 2024.
- Kymera Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $3.9 million in 2021, then skyrocketed by 76.02% to $6.9 million in 2022, then surged by 51.46% to $10.4 million in 2023, then skyrocketed by 53.96% to $16.1 million in 2024, then soared by 39.08% to $22.4 million in 2025.
- Its Accumulated Depreciation & Amortization was $22.4 million in Q3 2025, compared to $20.2 million in Q2 2025 and $18.1 million in Q1 2025.